Celia L. Culley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Celia L. Culley has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Erica D. Greanya
Department of Pharmacy, Island Health, 1952 Bay St, Victoria, BC, V8R 1J8, Canada
1 shared publication- Erica D. Greanya
Department of Pharmacy, Victoria General Hospital, 1 Hospital Way, Victoria, British Columbia, Canada V8Z 6R5; Faculty of Pharmaceutical Sciences, The University of British Columbia, 2405 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3
1 shared publication - I. Fan Kuo
Pharmaceutical, Laboratory, and Blood Services Division British Columbia Ministry of Health Vancouver British Columbia Canada
1 shared publication - Mary H. H. Ensom
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
1 shared publication Nicholas T. Edwards
Department of Pharmacy, Island Health, 1952 Bay St, Victoria, BC, V8R 1J8, Canada
1 shared publication- Peter Loewen
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication
Latest Publications
- 9 March 2017
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 39 (2) , 468-472
Patient preferences regarding atrial fibrillation stroke prophylaxis in patients at potential risk of atrial fibrillation
Background With an increasing number of options for atrial fibrillation (AF) stroke prophylaxis, there are several medication-related factors to consider. This study aimed to gain a better understanding of which preference factors influence patient decisions when selecting AF stroke prophylaxis. Objective To determine the factors that influence patient stroke prophylaxis decisions and preferred therapeutic options. Methods A questionnaire about AF stroke prophylaxis medication options was distributed to participants at risk of AF. Preferences were elicited through ranking and rating medication preference factor statements, then selecting most and least preferred treatment options. Results Reduced stroke risk and lowest risk of an intracranial haemorrhage (ICH) had the highest median preference factor ranking of 2 (IQR, 1–3.5 for stroke reduction; 2–4 for ICH risk). Reducing stroke risk, availability of a lab test to assess drug effect, and availability of an antidote were the preference factors with the highest ratings. Apixaban was the most preferred treatment option (44% blinded to drug name, 37% unblinded) while ‘No treatment’ was the least preferred option (48% blinded, 52% unblinded). Conclusions Reducing stroke risk and limiting ICH risk were the most important medication factors to participants. High inter-participant preference variability suggests the importance of including the patient in decision-making when selecting AF stroke prophylaxis.
- 9 March 2017
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 39 (2) , 468-472
Patient preferences regarding atrial fibrillation stroke prophylaxis in patients at potential risk of atrial fibrillation
Background With an increasing number of options for atrial fibrillation (AF) stroke prophylaxis, there are several medication-related factors to consider. This study aimed to gain a better understanding of which preference factors influence patient decisions when selecting AF stroke prophylaxis. Objective To determine the factors that influence patient stroke prophylaxis decisions and preferred therapeutic options. Methods A questionnaire about AF stroke prophylaxis medication options was distributed to participants at risk of AF. Preferences were elicited through ranking and rating medication preference factor statements, then selecting most and least preferred treatment options. Results Reduced stroke risk and lowest risk of an intracranial haemorrhage (ICH) had the highest median preference factor ranking of 2 (IQR, 1–3.5 for stroke reduction; 2–4 for ICH risk). Reducing stroke risk, availability of a lab test to assess drug effect, and availability of an antidote were the preference factors with the highest ratings. Apixaban was the most preferred treatment option (44% blinded to drug name, 37% unblinded) while ‘No treatment’ was the least preferred option (48% blinded, 52% unblinded). Conclusions Reducing stroke risk and limiting ICH risk were the most important medication factors to participants. High inter-participant preference variability suggests the importance of including the patient in decision-making when selecting AF stroke prophylaxis.
- 1 February 2015
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 25, 1-17
Lacosamide as adjunctive therapy in refractory epilepsy in adults: A systematic review
- 1 February 2015
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 25, 1-17
Lacosamide as adjunctive therapy in refractory epilepsy in adults: A systematic review